4//SEC Filing
Throne Jason 4
Accession 0001610717-23-000258
CIK 0001676725other
Filed
Sep 5, 8:00 PM ET
Accepted
Sep 6, 6:37 PM ET
Size
14.2 KB
Accession
0001610717-23-000258
Insider Transaction Report
Form 4
Throne Jason
VP, General Counsel
Transactions
- Sale
Common Stock
2023-09-01$30.03/sh−2,100$63,063→ 0 total - Sale
Common Stock
2023-09-05$30.03/sh−1,737$52,160→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-09-05−1,737→ 54,913 totalExercise: $12.86Exp: 2032-02-29→ Common Stock (1,737 underlying) - Exercise/Conversion
Common Stock
2023-09-01$12.86/sh+2,100$27,006→ 2,100 total - Exercise/Conversion
Common Stock
2023-09-05$12.86/sh+1,737$22,338→ 1,737 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-09-01−2,100→ 56,650 totalExercise: $12.86Exp: 2032-02-29→ Common Stock (2,100 underlying)
Footnotes (4)
- [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 29, 2023.
- [F2]This transaction was executed in multiple trades in prices ranging from $30.00 to $30.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This transaction was executed in multiple trades in prices ranging from $30.00 to $30.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Documents
Issuer
IDEAYA Biosciences, Inc.
CIK 0001676725
Entity typeother
Related Parties
1- filerCIK 0001790865
Filing Metadata
- Form type
- 4
- Filed
- Sep 5, 8:00 PM ET
- Accepted
- Sep 6, 6:37 PM ET
- Size
- 14.2 KB